Neophore Revenue and Competitors

Cambridge,

Location

#3578

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Neophore's estimated annual revenue is currently $3.1M per year.(i)
  • Neophore's estimated revenue per employee is $155,000

Employee Data

  • Neophore has 20 Employees.(i)
  • Neophore grew their employee count by 11% last year.

Neophore's People

NameTitleEmail/Phone
1
Executive Assistant To CEO & CFOReveal Email/Phone
2
CEOReveal Email/Phone
3
EVP, Drug DiscoveryReveal Email/Phone
4
Research Laboratory ManagerReveal Email/Phone
5
Chairman, NeoPhoreReveal Email/Phone
6
Principal Scientist - BiologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Neophore?

NeoPhore is creating novel small molecule immuno-oncology therapeutics. NeoPhore's drugs target genetic mechanisms that both clinical and lab validation studies suggest will promote neoantigen creation and diversity across numerous cancers. Alone or in combination with other cancer immunotherapies, drugs that spark cancer neoantigen creation are designed to stimulate the immune system and improve outcomes for patients who fail to benefit from the current generation of cancer immunity therapeutics.

keywords:N/A

N/A

Total Funding

20

Number of Employees

$3.1M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Neophore News

2022-04-06 - Aberrant R-loop-induced replication stress in MED12-mutant ...

Julian Blagg (NeoPhore, LTD and The Institute of Cancer Research, London, UK) for the kind gift of CCT251545. Funding. This work was supported...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4M20-9%$69M
#2
$2.9M20N/AN/A
#3
$1.5M20-47%N/A
#4
$3.1M2011%N/A
#5
$2M20-13%N/A